Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR

Pituitary

Volumn 14, Issue 2, 2011, Pages 148-156

  Vilar, Lucio ^a,e   Azevedo, Monalisa F ^b   Naves, Luciana Ansaneli ^b   Casulari, Luiz Augusto ^b   Albuquerque, José Luciano ^a   Montenegro, Renan M ^c   Montenegro Jr , Renan M ^c   Figueiredo, Patricia ^c   Nascimento, Gilvan C ^d   Faria, Manuel S ^d  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^b HOSPITAL UNIVERSITÁRIO DE BRASÍLIA   (Brazil)

^c FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^d FEDERAL UNIVERSITY OF MARANHÃO   (Brazil)

^e NONE   (Brazil)

Author keywords

Acromegaly; Cabergoline; Combination therapy; Octreotide LAR

Indexed keywords

CABERGOLINE; GROWTH HORMONE; LONG ACTING DRUG; OCTREOTIDE; PROLACTIN; SOMATOMEDIN C;

ACROMEGALY; ADULT; AGED; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG TOLERABILITY; EVENING DOSAGE; FEMALE; GROWTH HORMONE BLOOD LEVEL; HUMAN; HYPERPROLACTINEMIA; IMMUNOHISTOCHEMISTRY; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; TRANSSPHENOIDAL SURGERY; TUMOR VOLUME;

ACROMEGALY; ADENOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DELAYED-ACTION PREPARATIONS; DRUG RESISTANCE, NEOPLASM; ERGOLINES; FEMALE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; TIME FACTORS; YOUNG ADULT;

EID: 79958104562     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-010-0272-1     Document Type: Article

References (40)

1. Barkan A, Bronstein MD, Bruno OD et al (2010) Management of acromegaly in Latin America: expert panel recommendations. Pituitary 13:168-175
2. Ben-Shlomo A, Melmed S (2008) Acromegaly. Endocrinol Metab Clin North Am 37:101-122
3. Melmed S, Colao A, Barkan A et al (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 119:3189-3202
4. Nomikos P, Buchfelder M, Fahlbusch R (2005) The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol 152:379-387
5. Katznelson L (2008) An update on treatment strategies for acromegaly. Expert Opin Pharmacother 9:2273-2280
6. Melmed S (2009) Acromegaly: pathogenesis and treatment. J Clin Invest 119:3189-3202
7. Ben-Shlomo A, Melmed S (2008) Somatostatin agonists for treatment of acromegaly. Mol Cell Endocrinol 286:192-198
8. Freda PU (2003) How effective are current therapies for acromegaly? Growth Horm IGF Res 13(Suppl A):S144-S151
9. van der Lely AJ, Hutson KR, Trainer PJ et al (2001) Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358:1754-1759 (Pubitemid 33152999)
10. Colao A, Arnaldi G, Beck-Peccoz P et al (2007) Pegvisomant in acromegaly: why, when, how. J Endocrinol Invest 30:693-699 (Pubitemid 350104101)
11. Abs R, Verhelst J, Maiter D et al (1998) Cabergoline in the treatment of acromegaly: a study of 64 patients. J Clin Endocrinol Metab 83:374-378 (Pubitemid 28496509)
12. Vilar L, Czepielewski MA, Naves LA et al (2007) Substantial shrinkage of adenomas cosecreting growth hormone and prolactin with use of cabergoline therapy. Endocr Pract 13:396-402
13. Cozzi R, Attanasio R, Lodrini S, Lasio G (2004) Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf) 61:209-215 (Pubitemid 39093116)
14. Gatta B, Hau DH, Catargi B et al (2005) Re-evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patients. Clin Endocrinol (Oxf) 63: 477-478 (Pubitemid 41442345)
15. Mattar P, Alves Martins MR, Abucham J (2010) Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling IGF-I levels in acromegaly. Neuroendocrinol 92:120-127
16. Jallad RS, Bronstein MD (2009) Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide. Neuroendocrinol 90:82-92
17. Jaffe CA, Barkan AL (1992) Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am 21:713-725
18. Cozzi R, Attanasio R, Barausse M et al (1998) Cabergoline in acromegaly: a renewed role for dopamine agonist treatment? Eur J Endocrinol 139:516-521
19. Jackson SNJ, Fowler J, Howlett TA (1997) Cabergoline treatment of acromegaly: a preliminary dose finding study. Clin Endocrinol (Oxf) 46:745-749 (Pubitemid 27304460)
20. Muratori M, Arosio M, Gambino G et al (1997) Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J Endocrinol Invest 20:537-546 (Pubitemid 28014506)
21. Colao A, Ferone D, Marzullo P et al (1997) Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab 82:518-523 (Pubitemid 27068622)
22. Zanettini R, Antonini A, Gatto G et al (2007) Valve heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356:39-46 (Pubitemid 46041752)
23. Colao A, Galderisi M, Di Sarno A et al (2008) Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab 93:3777-3784
24. Bogazzi F, Buralli S, Manetti L et al (2008) Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. Int J Clin Pract 62:1864-1869
25. Vallette S, Serri K, Rivera J et al (2009) Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary 12:153-157
26. Herring N, Szmigielski C, Becher H et al (2009) Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol (Oxf) 70:104-108
27. Nachtigall LB, Valassi E, Lo J et al (2010) Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study. Clin Endocrinol (Oxf) 72:53-58
28. van der Klaauw AA, Bax JJ, Roelfsema F et al (2006) Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation. Growth Horm IGF Res 106:101-107
29. Rocheville M, Lange DC, Kumar U et al (2000) Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288:154-157 (Pubitemid 30203051)
30. Zatelli MC, Piccin D, Tagliati F et al (2005) Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro. J Mol Endocrinol 35:333-341 (Pubitemid 41556180)
31. Jaquet P, Gunz G, Saveanu A et al (2005) BIM- 23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs. universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. J Endocrinol Invest 28(11 Suppl International):21-27
32. Jaquet P, Gunz G, Saveanu A et al (2005) Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatinanalog therapy. Eur J Endocrinol 153:135-141 (Pubitemid 41030524)
33. Saveanu A, Lavaque GunzG et al (2002) Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM- 23A387, in supressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J Clin Endocrinol Metab 87:5545-5552 (Pubitemid 36034358)
34. Colao A, Pivonello R, Auriemma RS et al (2007) Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol 157:579-587 (Pubitemid 350187374)
35. Cozzi R, Attanasio R, Montini M et al (2003) Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab 88:3090-3098 (Pubitemid 36877477)
36. Jallad RS, Musolino NRC, Salgado L, Bronstein MD (2005) Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution. Clin Endocrinol (Oxf) 63: 168-175 (Pubitemid 41097985)
37. Ben-Shlomo A, Melmed S (2008) Somatostatin agonists for treatment of acromegaly. Mol Cell Endocrinol 286:192-198
38. Freda PU (2002) Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 87:3013-3018
39. Neggers SJ, van Aken MO, Janssen JA et al (2007) Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab 92:4598-4601 (Pubitemid 350223432)
40. Neggers SJ, van der Lely AJ (2009) Somatostatin analog and pegvisomant combination therapy for acromegaly. Nat Rev Endocrinol 5:546-552